Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)?: An evaluation of the risks and benefits of TPA from the patient's perspective

Journal of Clinical Epidemiology

Volumn 53, Issue 9, 2000, Pages 888-894

  Heyland, Daren K ^a   Gafni, Amiram ^b   Levine, Mitchell A H ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Decision making; Economic evaluations; Myocardial infarction; Outcomes assessments; Patient preferences; Thrombolytic therapy

Indexed keywords

STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; DRUG CHOICE; DRUG COST; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STROKE;

AGED; DECISION MAKING; FEMALE; FIBRINOLYTIC AGENTS; HUMAN; MALE; MIDDLE AGE; MYOCARDIAL INFARCTION; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RISK ASSESSMENT; STREPTOKINASE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033825438     PISSN: 08954356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-4356(99)00214-0     Document Type: Article

References (25)

1. Ridker P.M., O'Donnell C., Marder V.J., Hennekens C.H. Large scale trials of thrombolytic therapy for acute myocardial infarction. GISSI-2, ISIS-3, and GUSTO-1 Ann Intern Med. 119:1993;530-532. [Editorial].
2. Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ, for the GUSTO investigators. Holding GUSTO up to the light. Ann Intern Med 1994;120:876-881.
3. Ricker P.M., O'Donnell C., Murder V., Hennekens C.H. A response to "Holding GUSTO up to the light." Ann Intern Med. 120:1994;882-885.
4. Farkouh M.E., Lang J.D., Sackett D.L. Thrombolytic agents. The science of the art of choosing the better treatment Ann Intern Med. 120:1994;886-888. [Editorial].
5. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:1993;673-682.
6. Lee T.H. Cost effectiveness of tissue Plasminogen Activator. N Engl J Med. 332:1995;1443-1444. [Editorial].
7. Mark D.B., Hlatky M.A., Califf R.M., Naylor C.D., Lee K.L., Armstrong P.W.et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 332:1995;1418-1424.
8. Kalish S.C., Gurwitz J.H., Krumholz H.M., Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 10:1995;321-330.
9. O'Brien B., Heyland D.K., Richardson W.S., Levine M., Drummond M.F., for the Evidence-Based Medicine Working Group User's Guides to the medical literature. XI. How to use an economic analysis of clinical practice. B. What are the results and will they help me in caring for my patients? JAMA. 277:1997;1802-1806.
10. Eddy D. Anatomy of a decision. JAMA. 263:1990;441-444.
11. Kassirer J.P. Incorporating patient's preferences into medical decisions. N Engl J Med. 330:1994;1895-1896. [Editorial].
12. Levine M.N., Gafni A., Markham B., MacFarlane D. A bedside decision instrument to elicit a patient's preferences concerning adjuvant chemotherapy for breast cancer. Ann Intern Med. 117:1992;53-58.
13. Whelan T.J., Levine M.N., Gafni A.et al. Breast irradiation post lumpectomy. Development and evaluation of a decision instrument J Clin Oncology. 13:1995;847-853.
14. Sebban C., Browman G., Gafni A.et al. Design and validation of a bedside instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia. Am J Hematol. 48:1995;221-227.
15. Elit L.M., Levine M.N., Gafni A., Whelan T.J., Doig G., Streiner D.L., Rosen B. Patient's preferences for therapy in advanced epithelial ovarian cancer. Developing, testing and application of a bedside decision instrument Gynecologic Oncologic Journal. 62:1996;329-335.
16. Indications for fibrinolytic therapy in suspected acute myocardial infarction. Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients Lancet. 343:1994;311-322.
17. Stanek E.J., Cheng J.W.M., Peeples P.J., Simko R.J., Spinler S.A. Patient preferences for thrombolytic therapy in acute myocardial infarction. Med Decis Making. 17:1997;464-471.
18. Torrance GW. Health states worse than death. In: won Eimeren W, Englbrecht R, Flagle CD, editors. Third International Conference on Systems Science Health care. Berlin, Germany: 1984. Springer Verlag.
19. Mehrez A., Gafni A. The optimal treatment strategy - a patient's perspective. Management Science. 33:1987;1602-1612.
20. Bell D.E., Farquhar P.H. Perspective on utility theory. Operations Research. 34:1986;179-183.
21. Fishburn P.C. Expected utility. an anniversary and a new era Journal of Risk and Uncertainty. 1:1988;267-288.
22. Machina M.J. Choice under uncertainty. problems solved and unsolved Economics Perspective. 1:1987;121-154.
23. Tversky A., Kahneman D. Judgement under certainty. heuristics and biases Science. 185:1974;1124-1131.
24. Kahneman D., Tversky A. Prospect theory. an analysis of decisions under risk Econometrica. 47:1979;262-291.
25. O'Brien B., Goeree R., Gafni A., Torrance G.W., Pauly M.V., Erder H., Rusthoven J., Weeks J., Cahill M., LaMont B. Assessing the value of a new pharmaceutical. a feasibility study of contingent valuation in managed care Medical Care. 36:1998;370-384.